

UDC: 616-089.844-089.168-036.82/.86:575.11:577.1

DOI: 10.24061/2413-4260.XVI.2.60.2026.23

L. Sydorчук, R. Gumennyi

Bukovinian State Medical University of the Ministry
of Health of Ukraine
(Chernivtsi, Ukraine)

MOLECULAR AND GENETIC PATHWAYS
OF WOUND HEALING BY AGE IN
RECONSTRUCTIVE AND PLASTIC SURGERY:
A COHORT STUDY

Abstract.

Despite advances in surgical techniques and perioperative care, postoperative complications – including impaired wound healing, pathological scarring, infection, and flap or graft failure – remain a significant clinical problem, adversely affecting patient outcomes and satisfaction while increasing healthcare costs.

The Aim of this study is to evaluate age-dependent expression of the IL6, CCL2, MAPK1, MAPK8, IL10, MMP9, COL1A1 and COL3A1 in a cohort of women undergoing reconstructive and plastic surgery cohort, and to assess the molecular and genetic pathways involved in wound healing.

***Materials and Methods.** Ninety-five women participated in the prospective longitudinal cohort study and underwent reconstructive / plastic surgery. The mean age 35.48 ± 6.61 years (range: 19-57 years). All participants provided written informed consent prior to enrollment and subsequently underwent comprehensive demographic, clinical, instrumental, and laboratory assessments. The study was conducted in accordance with the principles of the Council of European Convention on Human Rights and Biomedicine. Ethical approval was obtained from the Biomedical Ethics Commission of Bukovinian State Medical University. Participants were stratified by age: <30 yr (24.21%), 30-39 years (44.21%), ≥ 40 yr (31.58%); and by the presence of postoperative complications: complicated cases (12.63%) and uncomplicated cases (87.67%). Transcriptional activity of IL6, CCL2, MAPK1, MAPK8, IL10, MMP9, COL1A1 and COL3A1 genes in peripheral blood was assessed by pathway-specific PCR array. Purified RNA was reverse-transcribed (RT) with a complementary DNA (cDNA). Statistical analysis was performed using Statistica 7.0 software (StatSoft Inc., USA) and Excel® 2016™. This study was conducted as part of an ongoing comprehensive Research Program of the Family Medicine Department at Bukovinian State Medical University «Improvement of diagnosis and prediction of hypertensive-mediated certain target organ damage and symptom control in comorbid pathology considering clinical-metabolic and molecular-genetic predictors» (State Registration No. 0124U002524; project period: 01 January 2024 to 31 December 2028).*

***Results.** Women ≥ 40 yr undergoing plastic and reconstructive breast surgery are characterised by a high-risk molecular profile for postoperative complications. This profile encompasses increased pro-inflammatory activity, reflected by elevated IL6 gene expression ($M = 0.75$; $p = 0.05$); enhanced proliferative and regenerative processes, indicated by MAPK1 expression ($M = 0.63$); and activated stress-related signalling pathways, evidenced by MAPK8 expression ($M = 1.64$; $p = 0.017$). It is further distinguished by intensive extracellular matrix remodeling with accelerated collagen and matrix degradation, reflected by elevated MMP9 expression ($M = 0.82$; $p = 0.002$); augmented fibrogenesis, manifested as a twofold increase in COL1A1 expression ($M = 1.53$; $p_1 = 0.017$), a comparatively modest increase in COL3A1 (1.69- and 0.75-fold), and a 2.55-fold upregulation of TGF β 1 2.55-fold ($p = 0.041$); and an immunosuppressive shift, reflected by a compensatory increase in IL10 expression ($M = 0.22$; $p_1 = 0.05$).*

A marked imbalance in the COL1A1/COL3A1 ratio (COL1A1 \gg COL3A1) was identified, representing the molecular basis of fibrosis and hypertrophic scar formation. Women 30-40 yr, by contrast, exhibited the most balanced gene expression profile, which may correspond to an optimal tissue reparative potential.

***Conclusion.** Women > 40 yr undergoing plastic and reconstructive breast surgery exhibit a molecular profile associated with a high risk of postoperative complications. Women 30-40 yr demonstrate a more balanced gene expression profile, consistent with a more favorable reparative tissue response and wound healing.*

***Key words:** Wound Healing; Gene Expression; Plastic and Reconstructive Breast Surgery; Inflammation; Women; Age; Tissue Response; Molecular and Genetic Mechanism; Regenerative Processes; Fibrogenesis.*

Introduction

Reconstructive and plastic surgery plays a crucial role in restoring form, function and quality of life in patients undergoing treatment for congenital anomalies, trauma, oncological conditions, degenerative diseases or aesthetic indications. The scale of these interventions is considerable: in the United States in 2015 alone, more than 1.5 million surgical procedures and over three million nonsurgical aesthetic interventions were performed [1]. Despite significant advances in surgical techniques, perioperative care, and biomaterials, postoperative complications remain a substantial clinical challenge. Impaired wound healing, excessive scar formation, surgical site infection, flap or graft failure, and chronic postoperative inflammation continue to adversely affect functional and aesthetic outcomes, increase healthcare costs, and compromise patient satisfaction [2-4].

Wound healing is a complex, tightly regulated biological process encompassing coordinated interactions among inflammatory mediators, immune cells, extracellular matrix remodeling, angiogenesis, and tissue regeneration [5; 6]. Dysregulation of any phase of this process – particularly the inflammatory and matrix remodeling phases – may result in delayed healing, hypertrophic scarring, fibrosis, or wound dehiscence. Complications associated with implant-based breast reconstruction are broadly classified as either short-term or long-term [7]. Short-term complications are considered perioperative events that may jeopardize the success of the reconstruction, including seroma, haematoma, infection, and skin envelope necrosis. Long-term complications do not typically pose an immediate risk of reconstructive failure; however, they encompass

unfavorable aesthetic outcomes – such as implant malposition, contour deformities, and rippling – more serious reconstructive sequelae, including severe capsular contracture or animation deformity, and rare systemic conditions, such as breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) and breast implant illness (BII). Mounting evidence indicates that individual variability in postoperative outcomes cannot be fully explained by surgical factors alone, underscoring the importance of host-related biological determinants [8].

Genetic and molecular mechanisms are now recognised as key contributors to interindividual differences in tissue repair and susceptibility to postoperative complications [5; 9; 10]. Polymorphisms and altered expression of genes involved in inflammatory signaling, immune regulation, extracellular matrix turnover, and angiogenesis have been associated with abnormal wound healing and pathological scar formation [11-13]. Cytokines such as interleukin-6 (IL-6) and interleukin-10 (IL-10), chemokines including C-C motif chemokine ligand 2 (CCL2), mitogen-activated protein kinases (MAPK1, MAPK8), matrix metalloproteinase-9 (MMP9), and structural extracellular matrix proteins (COL1A1, COL3A1) are among the key molecular mediators implicated in these processes. Alterations in their expression or interaction networks may shift the balance between physiological repair and pathological remodeling [14-17].

The present study was therefore designed to investigate the molecular and genetic pathways involved in the wound healing and the development of postoperative complications in reconstructive and plastic surgery.

The aim of the study is to evaluate age-dependent expression of IL6, CCL2, MAPK1, MAPK8, IL10, MMP9, COL1A1 and COL3A1 genes in a cohort of women undergoing reconstructive and plastic surgery, and to assess the molecular and genetic pathways involved in wound healing.

Material and methods

Clinical material was collected at the Limited Liability Company «Bukovinian Centre of Plastic and Aesthetic Surgery» (Chernivtsi city, UA) between 2024 and 2025. A total of 95 women were enrolled in the prospective longitudinal cohort study and underwent reconstructive / plastic surgery. The mean age 35.48 ± 6.61 years (range: 19-57 years). All participants provided written informed consent prior to enrolment, after which a comprehensive assessment was performed, encompassing demographic and clinical evaluation, instrumental examination (breast ultrasonography or mammography), and laboratory investigations (complete blood count and biochemical analysis). The study was conducted in accordance with the principles of the Convention on Human Rights and Biomedicine of the Council of Europe, the fundamental requirements of Good Clinical Practice (1996), and the ethical standards for medical research involving human participants set forth in the World Medical Association Declaration of Helsinki. Ethical approval was obtained from the Biomedical Ethics Commission of Bukovinian State Medical University (BSMU).

Women were stratified by age: <30 yr (24.21%), 30-39 yr (44.21%), and ≥ 40 yr (31.58%); by the presence of postoperative complications: complicated cases (12.63%) and uncomplicated cases (87.67%); by type of reconstructive or plastic surgery: augmentation mammoplasty (69.47%), reduction mammoplasty (5.26%), mastopexy (6.32%), mastopexy with mammoplasty (9.47%), implant replacement (7.37%), and implant removal (2.11%); and by type of complication: retromammary seroma (2.11%), capsular fibrosis (6.32%), implant retroposition with breast shape change (3.16%), and implant rupture (1.05%). A total of 24.21% of women had a history of surgical interventions at other anatomical sites (caesarean section, ear, nose and throat surgery, and appendectomy), and 14.74% a history of concomitant chronic conditions (cystitis, pyelonephritis, Gilbert syndrome, bronchitis, and meniscus tear).

Transcriptional activity of IL6, CCL2, MAPK1, MAPK8, IL10, MMP9, COL1A1 and COL3A1 genes in the peripheral blood was assessed by pathway-specific polymerase chain reaction (PCR) array using the iTaq Universal SYBR Green Supermix SMX500 set (Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., USA). Total RNA was isolated from blood leucocytes using GeneAll® Hybrid-RTM Blood RNA kit (GeneAll Biotechnology Co., Ltd., Korea) according to the manufacturer's instructions. The purified RNA subjected to reverse transcription (RT) with the cDNA iScript™ gDNA Clear Synthesis Kit (Bio-Rad Laboratories, Inc., USA). RNA samples with integrity values ranging from -2.0 to 2.2 were included in the analysis, and all reactions were performed in triplicate. Relative messenger RNA (mRNA) expression of target genes was quantified using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the reference gene and normalized by the $\Delta\Delta C_t$ method, as described previously [18; 19]. Fold changes in gene expression were calculated using the $2^{-\Delta\Delta C_t}$ formula.

Statistical analysis was performed using Statistica 7.0 software (StatSoft Inc., USA) and Excel® 2016™. Categorical variables were analysed by odds ratio (OR) with 95% confidence interval (CI) using the chi-square test (χ^2 , $df = 1$); Fisher exact test was applied when expected cell frequencies were below 5. A multivariate logistic regression model was additionally employed. Differences between groups were evaluated using Student's *t*-test (two-tailed, equal variances assumed; reported as mean, M), one-way analysis of variance (ANOVA), Pearson chi-square test, or the Wilcoxon-Mann-Whitney *U* test when data distribution deviated from normality, as determined by the Shapiro-Wilk or Kolmogorov-Smirnov tests (*Z*-score; Me (Q1; Q3) with interquartile range – IQR). Statistical significance was set at $p < 0.05$.

This study was conducted as part of an ongoing Research Program of the Family Medicine Department at Bukovinian State Medical University «Improvement of Diagnosis and Prediction of Hypertension-Mediated Target Organ Damage and Symptom Control in Comorbid Pathology Considering Clinical, Metabolic, and Molecular Genetic Predictors» (State Registration No. 0124U002524; project period: 01 January 2024 to 31 December 2028).

Results and Discussion

The relative normalized mRNA expression levels ($\Delta\Delta Ct$) of IL6, MAPK1, MAPK8, MMP9, and TGF β 1 genes in peripheral blood, with GAPDH as the reference gene, are presented in Figure 1. Genes associated with inflammation, signal transduction, and extracellular matrix remodeling,

accompanied by pronounced inter-individual variability, demonstrate predominantly low-to-moderate systemic expression. This expression pattern may reflect a balance between pro- and anti-inflammatory mechanisms, suggesting a predominantly local nature of molecular alterations that are not consistently reflected in circulating blood.




Figure 1. Relative normalized mRNA expression of genes IL-6, CCL2, MAPK1, MAPK8, IL-10, MMP9, COL1A1, COL3A1, TGF β 1 in peripheral blood samples, using GAPDH as the reference gene ($-2\sim 2$ LogN mRNA, $\Delta\Delta Ct$).

Normalised mRNA expression analysis of key immune-inflammatory, signalling, and matrix-remodelling genes revealed a clear age-dependent molecular response in women undergoing plastic and reconstructive breast surgery (Table 1). The most pronounced changes were observed in women >40 yr, indicating an increasing molecular predisposition to impaired tissue healing. In women <30 yr, the mean IL6 expression level was reduced ($M = -0.70$), suggesting a less pronounced

inflammatory response. In the 30-40-yr group, a moderate increase – though remaining negative – was observed ($M = -0.31$), whereas women >40 yr demonstrated a marked elevation in IL6 expression ($M = 0.75$; $p = 0.05$), indicating age-related amplification of the pro-inflammatory activity. This finding reflects enhanced systemic inflammation associated with an increased risk of prolonged inflammation, seroma formation, and potential infectious complications [20; 21].

Table 1

Genetic-molecular panel of wound healing markers by level of normalized gene expression depending on the age of the operated women

Marker	mRNA level Expression, Me (Q1; Q3); M		
	<30 yr, n=12	30-40 yr, n=24	>40 yr, n=14
IL-6	0 (-2.21; 1.06); M: -0.70	0 (-0.49; 0.91); M: -0.31	0 (0; 1.69); M: 0.75 ($p=0.05$)
CCL2	-0.46 (-0.55; 1.84); M: 0.53	0.01 (-2.42; 0.88); M: -1.84	0 (-0.66; 1.79); M: 0.05
MAPK1	0.32 (-0.40; 1.12); M: -0.09	0 (-0.74; 1.05); M: 0.04	0.48 (-0.99; 1.43); M: 0.63
MAPK8	1.03 (-0.56; 2.70); M: 1.01	-0.45 (-2.57; 1.07); M: -0.66 ($p=0.028$)	0.78 (-0.18; 3.43); M: 1.64 ($p_1=0.017$)
IL-10	-0.82 (-3.96; 1.60); M: -0.87	-0.76 (-0.90; 0.23); M: -1.06	1.14 (-1.30; 1.30); M: 0.22 ($p_1=0.05$)
MMP9	-0.20 (-2.49; 1.54); M: -0.54	-0.72 (-3.13; 0.44); M: -1.73	0.83 (0.23; 1.81); M: 0.82 ($p_1=0.002$)
COL1A1	0.34 (-1.26; 2.46); M: 0.70	-0.63 (-1.71; 1.04); M: -0.40	0.55 (-0.22; 3.75); M: 1.53 ($p_1=0.017$)
COL3A1	0.80 (0.04; 2.05); M: 0.42	0.03 (0; 0.39); M: -0.04	0.72 (-0.60; 1.04); M: 0.71
TGF β 1	1.50 (1.25; 1.75) M: 1.50	0.80 (-1.10; 2.58) M: 0.72	3.82 (3.57; 4.07) M: 3.82 ($p=0.041$)

Note. p – significance of differences with group <30 years; p_1 – significance of differences with 30-40 yr group.

CCL2 gene expression exhibited the greatest variability in women <30 yr ($M = 0.53$) (Table 1). In the 30-40-yr group, a decrease in mean expression was observed ($M = -1.84$), possibly reflecting reduced chemotactic activity. In women >40 yr, expression values stabilized near zero ($M = 0.05$). Age-related activation of monocyte-macrophage recruitment may contribute to chronic inflammation, fibrotic processes, and imbalance of M1/M2 macrophage polarization [22].

MAPK1 expression demonstrated a gradual age-related increase, from near-neutral values in younger age groups to higher levels in women >40 yr ($Me = 0.48$; $M = 0.63$), reflecting enhanced proliferative and regenerative signaling. The most pronounced age-related differences were observed for MAPK8 (JNK): high expression was detected in women <30 yr ($M = 1.01$), significantly lower levels in the 30-40-yr group ($M = -0.66$; $p = 0.028$), and a subsequent significant increase in women >40 yr ($M = 1.64$; $p_1 = 0.017$), indicating age-related activation of stress-associated signaling pathways. The lowest normalized expression levels of MAPK1 and MAPK8 were observed in women 30-40 yr, which may reflect reduced cellular proliferation or stress signaling outside a conditionally optimal age range (<30 and >40 yr). Activation of the JNK pathway is associated with oxidative stress, apoptosis, and impaired angiogenesis [23], constituting a molecular basis for the risk of flap necrosis and delayed wound healing.

In women <40 yr, IL10 expression was reduced ($M = -0.87$ and -1.06 , respectively), indicating limited anti-inflammatory compensation. Women >40 yr, by

contrast, exhibited increased normalized IL10 expression ($Me = 1.14$; $M = 0.22$; $p_1 = 0.05$) (Table 1), likely representing an adaptive response to intensified inflammation. This may reflect a compensatory immunosuppressive response to excessive or chronic inflammation, which simultaneously limits effective antibacterial defense and promotes infectious complications [21; 24; 25].

MMP9 expression increased with age and reached its maximum in women >40 yr ($Me = 0.83$; $M = 0.82$; $p_1 = 0.002$), exceeding levels in younger women by 1.37- and 2.55-fold ($M = -0.54$ and -1.73 , respectively). This finding indicates intensified collagen and extracellular matrix degradation, wound matrix instability, and an increased risk of seroma formation and tissue dehiscence.

Both COL1A1 and COL3A1 genes demonstrated increased expression in women ≥ 40 yr, particularly COL1A1, which increased approximately twofold (2.19 and 1.93, respectively), with a wide interquartile range (Table 1, Fig. 2). COL1A1 expression was lowest in women 30-40 yr ($M = -0.40$) and increased significantly in women >40 yr ($Me = 0.55$; $M = 1.53$; $p_1 = 0.017$), indicating age-related enhancement of fibrogenesis. In women <30 yr, relatively high COL3A1 expression was observed ($M = 0.42$), which decreased in the 30-40-yr group ($M = -0.04$) and increased again after 40 years ($M = 0.71$), consistent with changes in connective tissue remodeling phases. This pattern reflects activation of fibrogenesis and imbalance of the COL1A1/COL3A1 ratio ($COL1A1 \gg COL3A1$), constituting the molecular basis of fibrosis and hypertrophic scarring.




Figure 2. Relative normalized mRNA expression ($\Delta\Delta C_t$) of the studied genes in peripheral blood samples, with GAPDH as the reference gene.

In women <30 yr, TGF β 1 gene expression was moderate and relatively stable ($Me = 1.50$; Q1-Q3: 1.25-1.75; $M = 1.50$), corresponding to physiological fibrogenic regulation and balanced tissue repair. In the 30-40-yr group, a decrease in central tendency was observed ($Me = 0.80$; Q1-Q3: -1.10 to 2.58 ; $M = 0.72$), accompanied by substantial expansion of the interquartile range, indicating heterogeneity of TGF β 1 expression potentially related to hormonal fluctuations, metabolic factors, or individual differences in wound-healing regulation. In women ≥ 40 yr, TGF β 1 expression increased 2.55-fold and nearly fivefold compared with younger groups ($p = 0.041$), with a narrow interquartile range (Table 1). In the majority of participants, transcriptional activity of TGF β 1 was not detected, possibly attributable to its transient expression,

post-transcriptional regulation, or predominantly local (tissue-specific) activation not reflected in peripheral blood.

To provide an integrated assessment of molecular risk for postoperative complications, a Molecular Complication Risk Index (MCRI) was developed. The index is based on a weighted sum of normalized expression levels of genes involved in inflammation, stress signaling, and extracellular matrix remodeling (wound healing). Given that gene expression values are presented in folds ($\Delta\Delta C_t$), rank-based normalization was applied for each gene: low expression ($Me \leq Q1$) = 0 points; moderate expression ($Q1 < Me \leq Q3$) = 1 point; high expression ($Me > Q3$) = 2 points. The expected age-related stratification of postoperative complication risk is presented in Table 2.

Table 2

Expected age-related stratification of the risk of postoperative complications

Age	Molecular profile	Expected result of MCRI, points
<30 yr	Moderate inflammation, active ECM	5-8
30-40 yr	Balanced response	3-6
>40 yr	High activity of inflammation +MMP9 + MAPK8 + COL1A1 + TGFβ1	9-14

Note. ECM – extracellular matrix

According to MCRI values: 0-5 points indicate low risk of postoperative complications (physiological healing); 6-10 points indicate moderate risk (seroma formation, prolonged inflammation); MCRI ≥11 points indicate high risk (infection, necrosis, fibrosis, capsular contracture, etc). The highest MCRI values, corresponding to an unfavorable molecular profile, are associated with women >40 yr.

Following reconstructive breast surgery, tissues within the wound area frequently experience hypoxia. This condition activates hypoxia-inducible factor-1α (HIF-1α), a key transcription factor that regulates cellular adaptation to hypoxia and initiates the expression of genes involved in angiogenesis, metabolism, and cell survival [20; 26]. Under reduced oxygen tension, HIF-1α becomes stabilized and promotes the synthesis of vascular endothelial growth factor (VEGF), which is critical for neovascularization and tissue repair.

Dysregulation of this pathway – whether driven by chronic inflammation, oxidative stress, or comorbid conditions – may result in impaired tissue regeneration and fibrosis, thereby compromising wound healing and promoting pathological scarring. Under these conditions, the synthesis of transforming growth factor-β (TGF-β) is activated. TGF-β plays a dual role [27]: under physiological conditions, it stimulates cellular proliferation and tissue repair, enhances collagen synthesis (COL1A1, COL3A1), and suppresses extracellular matrix degradation through inhibition of matrix metalloproteinases (MMPs); during prolonged inflammation, however, excessive activation of TGF-β promotes pathological extracellular matrix accumulation, fibroblast activation, and the development of fibrosis [28; 29].

This mechanism is of particular relevance to wound healing following major surgical procedures and may be associated with increased tissue stiffness, contracture formation, and aesthetic complications after breast reconstruction [30].

Conclusion

Women ≥40 yr undergoing plastic and reconstructive breast surgery exhibit a molecular profile associated with a high risk of postoperative complications, characterised by enhanced pro-inflammatory signaling (IL6), activation of stress-related pathways (MAPK8), intensified extracellular matrix remodeling and collagen degradation (MMP9), increased fibrogenesis (COL1A1, TGFβ1), and a compensatory immunosuppressive response (IL10). The pronounced imbalance in the COL1A1/COL3A1 ratio constitutes a molecular basis for fibrosis and hypertrophic scar formation. Women 30-40 yr, by contrast, demonstrate a more balanced gene expression profile, consistent with a more favorable reparative tissue response and wound healing.

Prospects for further research. Include prospective validation of the proposed molecular risk index, investigation of tissue-specific gene expression dynamics, and assessment of personalised perioperative strategies aimed at reducing postoperative complications in high-risk age groups.

Contribution of co-authors to the preparation of the manuscript. L. Sydorчук – conceptualisation, writing (original draft), software, validation, supervision and project administration; R. Gumennyi – methodology, writing (review and editing), visualisation, and funding acquisition. All authors reviewed the final version of the manuscript and consented to its publication.

Conflict of interest. The authors declare no conflict of interest.

Use of Artificial Intelligence. No generative artificial intelligence tools were used in the preparation of this manuscript.

Sources of funding. The study was self-funded.

References:

- Montrief T, Bornstein K, Ramzy M, Koyfman A, Long BJ. Plastic Surgery Complications: A Review for Emergency Clinicians. *West J Emerg Med.* 2020;21(6):179-89. DOI: <https://doi.org/10.5811/westjem.2020.6.46415>
- Sen CK. Human Wound and Its Burden: Updated 2020 Compendium of Estimates. *Adv Wound Care (New Rochelle).* 2021;10(5):281-92. DOI: <https://doi.org/10.1089/wound.2021.0026>
- Skerritt L, Gooney M, Sheahan L. The provision of wound care and management in a community healthcare setting: an exploratory study. *J Wound Care.* 2025;34(1):74-87. DOI: <https://doi.org/10.12968/jowc.2024.0108>
- Smolanka II, Bagmut IY, Sheremet MI, Lyashenko AO, Movchan OV, Smolanka II Jr, et al. Delayed breast reconstruction with tram-flap and various modifications after radical mastectomy. *J Med Life.* 2021;14(6):847-52. DOI: <https://doi.org/10.25122/jml-2021-0354>
- Peña OA, Martin P. Cellular and molecular mechanisms of skin wound healing. *Nat Rev Mol Cell Biol.* 2024;25(8):599-616. DOI: <https://doi.org/10.1038/s41580-024-00715-1>
- Amjadian S, Fatemi MJ, Moradi S, Hesarak M, Mohammadi P. mir-182-5p regulates all three phases of inflammation, proliferation, and remodeling during cutaneous wound healing. *Arch Dermatol Res.* 2024 May 25;316(6):274. DOI: <https://doi.org/10.1007/s00403-024-03079-w>

7. Meshkin DH, Firriolo JM, Karp NS, Salibian AA. Management of complications following implant-based breast reconstruction: a narrative review. *Ann Transl Med.* 2023;11(12):416. DOI: <https://doi.org/10.21037/atm-23-1384>
8. Ogawa R. Keloid and hypertrophic scars. UpToDate [Internet]. 2026 [update 2026 Mar 2; cited 2026 May 3]. Available from: <https://www.uptodate.com/contents/keloids-and-hypertrophic-scars/print>
9. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. [updated 2023 Jun 12; cited 2026 May 7]. Wallace HA, Basehore BM, Zito PM. Wound Healing Phases. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK470443>
10. Liu J, Yan J, Qi S, Zhang J, Zhang X, Zhao Y. The PI3K/AKT/mTOR pathway in scar remodeling and keloid formation: mechanisms and therapeutic perspectives. *Front Pharmacol.* 2025;16:1678953. DOI: <https://doi.org/10.3389/fphar.2025.1678953>
11. Riaz M, Iqbal MZ, Klar AS, Biedermann T. Immunomodulatory Mechanisms of Chronic Wound Healing: Translational and Clinical Relevance. *MedComm (2020).* 2025;6(11): e70378. DOI: <https://doi.org/10.1002/mco2.70378>
12. Dand N, Ung CY, Saklatvala JR, Simpson MA, Barker JN, Shaw TJ, et al. GWAS Meta-Analysis Identifies Susceptibility Loci for Keloids and Hypertrophic Scarring in Europeans. *Journal of Investigative Dermatology.* 2025;145(6):1538-40.e8. DOI: <https://doi.org/10.1016/j.jid.2024.12.011>
13. Téot L, Mustoe TA, Middelkoop E, Gauglitz G, editors. Textbook on Scar Management: State of the Art Management and Emerging Technologies [Internet]. Cham (CH): Springer; 2020 [cited 2026 May 1]. Chapter 8. Sadiq A, Khumalo NP, Bayat A. Genetics of Keloid Scarring. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK586075/> DOI: http://dx.crossref.org/10.1007/978-3-030-44766-3_8
14. Sydorчук LP, Sakovets OP. The heat shock protein 70-2 gene (rs1061581) associates with the acute otitis medium in children. *Neonatology, surgery and perinatal medicine.* 2025;15(1):38-43. DOI: <https://doi.org/10.24061/2413-4260.XV.1.55.2025.6>
15. Latoni DI, McDaniel DC, Tsao H, Tsao SS. Update on the Pathogenesis of Keloid Formation. *JID Innovations.* 2024;4(6):100299. DOI: <https://doi.org/10.1016/j.xjidi.2024.100299>
16. Bi S, Liu R, Wu B, He L, Gu J. Bioinformatic Analysis of Key Genes and Pathways Related to Keloids. *Biomed Res Int.* 2021;2021:5897907. DOI: <https://doi.org/10.1155/2021/5897907>
17. Rose-John S. Interleukin-6 signalling in health and disease. *F1000Res.* 2020;9: F1000 Faculty Rev-1013. DOI: <https://doi.org/10.12688/f1000research.26058.1>
18. Sydorчук AR, Sydorчук LP, Gutnitska AF, Dzhuryak VS, Kryvetska II, Sydorчук RI, et al. Endothelium function regulation markers and carotid intima-media thickness in arterial hypertension depending on NOS3 (rs2070744) and GNB3 (rs5443) genes polymorphism: a prospective case-control study. *Endocrine Regulations.* 2022;56(2):104-14. DOI: <https://doi.org/10.2478/enr-2022-0012>
19. Sydorчук A, Sydorчук L, Gutnitska A, Vasyuk V, Tkachuk O, Dzhuryak V, et al. The role of NOS3 (rs2070744) and GNB3 (rs5443) genes' polymorphisms in endothelial dysfunction pathway and carotid intima-media thickness in hypertensive patients. *Gen Physiol Biophys.* 2023;42(2):179-90. DOI: https://doi.org/10.4149/gpb_2022060
20. Peng J, Zhu H, Ruan B, Duan Z, Cao M. miR-155 promotes m6A modification of SOX2 mRNA through targeted regulation of HIF-1 α and delays wound healing in diabetic foot ulcer in vitro models. *J Diabetes Investig.* 2025;16(1):60-71. DOI: <https://doi.org/10.1111/jdi.14327>
21. Wong RSY, Tan T, Pang ASR, Srinivasan DK. The role of cytokines in wound healing: from mechanistic insights to therapeutic applications. *Explor Immunol.* 2025;5:1003183. <https://doi.org/10.37349/ei.2025.1003183>
22. Hirokatsu Umeyama, Jie Ding, Antoinette Nguyen, Servet Elcin Alpat, Josue R Silva, et al. The Roles of SDF-1/CXCR4, MCP-1/CCR2 and CCL5/CCR5 Chemokine Pathway in Hypertrophic Scarring. *International Journal of Medical Science and Health Research.* 2021;5(2):181-201. DOI: <http://dx.doi.org/10.51505/ijmshr.2021.5215>
23. Yu J, Li X, Cao J, Zhu T, Liang S, Du L, et al. Components of the JNK-MAPK pathway play distinct roles in hepatocellular carcinoma. *J Cancer Res Clin Oncol.* 2023;149(19):17495-509. DOI: <https://doi.org/10.1007/s00432-023-05473-9>
24. Gao M, Guo H, Dong X, Wang Z, Yang Z, Shang Q, et al. Regulation of inflammation during wound healing: the function of mesenchymal stem cells and strategies for therapeutic enhancement. *Front Pharmacol.* 2024;15:1345779. DOI: <https://doi.org/10.3389/fphar.2024.1345779>
25. Fang X, Wang Y, Chen H, Yan Z, Jin S, Wu Y, et al. Hypertrophic Scarring and Keloids: Epidemiology, Molecular Pathogenesis, and Therapeutic Interventions. *MedComm.* 2025;6(10): e70381. DOI: <https://doi.org/10.1002/mco2.70381>
26. Song B, Zhu Y, Zhao Y, Wang K, Peng Y, Chen L, et al. Machine learning and single-cell transcriptome profiling reveal regulation of fibroblast activation through THBS2/TGF β 1/P-Smad2/3 signalling pathway in hypertrophic scar. *Int Wound J.* 2024;21(3): e14481. DOI: <https://doi.org/10.1111/iwj.14481>
27. Nahornyj OV, Ziablitsev SV. Patohenetychna rol transformuiuchoho faktora rostu beta (TGF- β) v mekhanizmakh rozvytku diabetychnoi nefropatii (ohliad literatury) [Pathogenetic role of transforming growth factor beta (TGF- β) in the mechanisms of development of diabetic nephropathy (literature review)]. *Medical Science of Ukraine (MSU).* 2025;21(1):128-39. DOI: <https://doi.org/10.32345/2664-4738.1.2025.16> (in Ukrainian)
28. Hong YK, Chang YH, Lin YC, Chen B, Guevara BEK, Hsu CK. Inflammation in Wound Healing and Pathological Scarring. *Adv Wound Care (New Rochelle).* 2023;12(5):288-300. DOI: <https://doi.org/10.1089/wound.2021.0161>
29. Sydorчук L, Gumennyi R, Sydorчук A, Batih I, Vasiuk V, Sydorчук R, et al. Genetic Modulation of Wound Healing Pathways and Postoperative Risk in Plastic and Reconstructive Surgery: A Cohort Study. *J Clinical Medicine.* 2026;15(7):2794. DOI: <https://doi.org/10.3390/jcm15072794>
30. Mony MP, Harmon KA, Hess R, Dorafshar AH, Shafikhani SH. An Updated Review of Hypertrophic Scarring. *Cells.* 2023;12(5):678. DOI: <https://doi.org/10.3390/cells12050678>

МОЛЕКУЛЯРНІ ТА ГЕНЕТИЧНІ ШЛЯХИ ЗАГОЄННЯ РАН ЗАЛЕЖНО ВІД ВІКУ У РЕКОНСТРУКТИВНІЙ ТА ПЛАСТИЧНІЙ ХІРУРГІЇ: КОГОРТНЕ ДОСЛІДЖЕННЯ

Л. П. Сидорчук, Р. М. Гуменний

Буковинський державний медичний університет МОЗ України
(м. Чернівці, Україна)

Резюме.

Незважаючи на досягнення в хірургічних техніках та періопераційному догляді, післяопераційні ускладнення, включаючи порушення загоєння ран, патологічне рубцювання, інфекція та відторгнення клаптя або трансплантата, залишаються значною клінічною проблемою, негативно впливаючи на результати та задоволеність пацієнтів, одночасно збільшуючи витрати на охорону здоров'я.

Мета. Дослідити експресію генів IL6, CCL2, MAPK1, MAPK8, IL10, MMP9, COL1A1 та COL3A1 залежно від віку у когорті жінок, які перенесли реконструктивну та пластичну хірургію, а також оцінка молекулярних та генетичних шляхів, що беруть участь у загоєнні ран.

Матеріал та методи. У проспективному поздовжньому когортному дослідженні взяли участь 95 жінок, яким було проведено реконструктивну/пластичну хірургію. Середній вік $35,48 \pm 6,61$ років (від 19 до 57 років). Всі жінки підписали інформовану згоду на участь у дослідженні, після чого їм було виконано комплекс демографічних, клінічних, інструментальних та лабораторних обстежень. Дослідження проводилося відповідно до принципів Ради Європи з прав людини та біомедицини. Етичне схвалення на проведення дослідження отримано від Комісії з біомедичної етики Буковинського державного медичного університету. Жінки були розподілені за віком: <30 років (24,21%), 30-39 років (44,21%), ≥ 40 років (31,58%); за наявністю ускладнень (наявні – 12,63%, без ускладнень – 87,67%). Транскрипційну активність генів IL6, CCL2, MAPK1, MAPK8, IL10, MMP9, COL1A1 та COL3A1 у периферичній крові досліджували за допомогою ПЛР-чипу, специфічного для певних шляхів. Очищена РНК пройшла зворотну транскрипцію (ЗТ) з кДНК. Статистичний аналіз проведено за допомогою програмного забезпечення Statistica 7.0 (StatSoft Inc, США) та Excel® 2016™. Дослідження було проведено в рамках поточної комплексної науково-дослідної програми кафедри сімейної медицини Буковинського державного медичного університету «Удосконалення діагностики та прогнозування гіпертонічного ураження певних органів-мішеней і контроль симптомів при супутніх захворюваннях з урахуванням клініко-метаболических та молекулярно-генетичних предикторів» (державна реєстрація № 0124U002524; термін виконання: з 1 січня 2024 року по 31 грудня 2028 року).

Результати дослідження. Жінки віком ≥ 40 років, які перенесли пластичні та реконструктивні операції на молочній залозі, характеризуються високим молекулярним профілем ризику післяопераційних ускладнень, який включає підвищену прозапальну активність, що відображається збільшеною експресією гена IL6 ($M = 0,75$; $p = 0,05$), посиленням проліферативних та регенеративних процесів за експресією гена MAPK1 ($M = 0,63$) та активацію сигнальних шляхів, пов'язаних зі стресом, про що свідчить експресія MAPK8 ($M = 1,64$; $p = 0,017$). Цей профіль також характеризується інтенсивним ремоделюванням позаклітинного матриксу та посиленою деградацією колагену та матриксу, що відображається підвищеною експресією MMP9 ($M = 0,82$; $p = 0,002$), а також посиленням фіброгенезом з дворазовим збільшенням експресії COL1A1 ($M = 1,53$; $p_1 = 0,017$), більш помірним збільшенням COL3A1 (в 1,69 та 0,75 рази) та вираженою підвищеною регуляцією TGF β 1 у 2,55 разу ($p = 0,041$). Крім того, спостерігається імуносупресивний зсув, що відображається компенсаторним збільшенням експресії IL10 ($M = 0,22$; $p_1 = 0,05$).

Встановили помітний дисбаланс у співвідношенні COL1A1/COL3A1 (COL1A1 \gg COL3A1), що відображає молекулярну основу фіброзу та утворення гіпертрофічних рубців. Натомість, жінки віком 30-40 років демонстрували найбільш збалансований профіль експресії генів, що може відповідати оптимальному потенціалу репарації тканин.

Висновки. Жінки віком понад 40 років, які перенесли пластичні, чи/та реконструктивні хірургічні втручання на молочній залозі, демонструють молекулярний профіль, асоційований із високим ризиком післяопераційних ускладнень. Жінки віком 30-40 років демонструють більш збалансований профіль експресії генів, що відповідає сприятливішій репаративній відповіді тканин та загоєнню ран.

Ключові слова: загоєння ран; експресія генів; пластична та реконструктивна хірургія молочної залози; запалення; жінки; вік; тканинна відповідь; молекулярно-генетичний механізм; регенеративні процеси; фіброгенез.

Contact Information:

Larysa Sydorчук – Doctor of Medicine, Full Professor, Head of the Family Medicine Department, Bukovinian State Medical University (Chernivtsi, Ukraine).

e-mail: lsydorчук@bsmu.edu.ua

ORCID ID: <https://orcid.org/0000-0001-9279-9531>

Scopus Author ID: 8428375700

Web of Science ResearcherID: B-7382-2017

Ruslan Gumennyi – Surgeon, Postgraduate Student, Department of Family Medicine, Bukovinian State Medical University (Chernivtsi, Ukraine).

e-mail: plastart.com.ua@gmail.com

ORCID ID: <https://orcid.org/0009-0009-9599-0361>

Контактна інформація:

Сидорчук Лариса Петрівна – доктор медичних наук, професор, завідувач кафедри сімейної медицини Буковинського державного медичного університету (м. Чернівці, Україна).

e-mail: lsydorчук@bsmu.edu.ua

ORCID ID: <https://orcid.org/0000-0001-9279-9531>

Scopus Author ID: 8428375700

Web of Science ResearcherID: B-7382-2017

Гуменний Руслан Миколайович – лікар-хірург, аспірант кафедри сімейної медицини Буковинського державного медичного університету (м. Чернівці, Україна).

e-mail: plastart.com.ua@gmail.com

ORCID ID: <https://orcid.org/0009-0009-9599-0361>

Received: February 23, 2026

Accepted: May 28, 2026

Published: June 29, 2026

